Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $13.75
  • 50 Day Moving Average: $17.47
  • 200 Day Moving Average: $16.02
  • 52-Week Range: $10.52 - $19.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.82
  • P/E Growth: 2.12
  • Market Cap: $1.82B
  • Outstanding Shares: 136,732,000
  • Beta: 1.65
  • Net Margins: -68.30%
  • Return on Equity: -8,769.15%
  • Return on Assets: -27.37%
  • Debt-to-Equity Ratio: -6.25%
  • Current Ratio: 4.02%
  • Quick Ratio: 3.89%
Additional Links:
Companies Related to Nektar Therapeutics:

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.00 (72.41% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetDetails
10/1/2016Piper Jaffray Cos.Set Price TargetBuy$25.00View Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00View Rating Details
9/8/2016Jefferies GroupReiterated RatingBuyView Rating Details
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details
2/12/2016William BlairReiterated RatingBuyView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
Current Year EPS Consensus Estimate: $-1.1 EPS
Next Year EPS Consensus Estimate: $-0.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.31)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
News IconBiotech stocks for your portfolio: ZIOPHARM Oncology, Inc. (ZIOP), Nektar Therapeutics (NKTR) - The Independent Republic (NASDAQ:NKTR) - October 21 at 9:50 AM
News IconBiotech Stocks Worth a Closer Look: Cerulean Pharma Inc. (NASDAQ:CERU), Nektar Therapeutics (NASDAQ:NKTR) - The Voice Registrar (NASDAQ:NKTR) - October 20 at 6:45 PM logoNektar Therapeutics (NASDAQ:NKTR) Files An 8-K - Market Exclusive (NASDAQ:NKTR) - October 20 at 6:45 PM logoNektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing - (NASDAQ:NKTR) - October 20 at 6:45 PM
News IconUnorthodox Volume Noted for Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - October 20 at 12:11 PM
News IconVolume Popping Today for Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - October 20 at 12:11 PM logoNektar Therapeutics (NASDAQ:NKTR) Files An 8-K (NASDAQ:NKTR) - October 20 at 12:11 PM logoInvestors Grab NKTR Even Cheaper Than Its Secondary Stock Offering (NASDAQ:NKTR) - October 20 at 11:00 AM
News IconUps And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR) (NASDAQ:NKTR) - October 20 at 4:48 AM logoNektar Therapeutics shares fall on secondary stock offering (NASDAQ:NKTR) - October 19 at 6:46 PM logoNektar Therapeutics Down 23.3% Since SmarTrend Downtrend Call (NKTR) (NASDAQ:NKTR) - October 19 at 6:46 PM logoETF’s with exposure to Nektar Therapeutics : October 19, 2016 (NASDAQ:NKTR) - October 19 at 6:46 PM logoNektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing (NASDAQ:NKTR) - October 19 at 6:46 PM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:NKTR) - October 19 at 6:46 PM
News IconNektar Therapeutics Prices Public Offering of Shares of Common Stock (NASDAQ:NKTR) - October 19 at 11:30 AM logoNektar Slides on Secondary Offering Pricing (NASDAQ:NKTR) - October 19 at 11:30 AM logoNektar Therapeutics Breaks Below 200-Day Moving Average - Notable for NKTR (NASDAQ:NKTR) - October 18 at 6:17 PM logoWhy W.W. Grainger, Badger Meter, and Nektar Therapeutics Slumped Today (NASDAQ:NKTR) - October 18 at 6:17 PM logoNektar Therapeutics Becomes Oversold (NKTR) (NASDAQ:NKTR) - October 18 at 2:14 PM logoNektar launches $175M equity offering (NASDAQ:NKTR) - October 17 at 6:20 PM logoNektar Therapeutics (NKTR) Announces $175M Common Stock Offering (NASDAQ:NKTR) - October 17 at 6:20 PM logo4:01 pm Nektar Therapeutics announces a $175 mln underwritten public offering of common stock (NASDAQ:NKTR) - October 17 at 6:20 PM logoNektar Therapeutics Announces Public Offering of Shares of Common Stock (NASDAQ:NKTR) - October 17 at 6:20 PM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Othe (NASDAQ:NKTR) - October 17 at 6:20 PM
News IconShare Value Diminishing Over Past Month: Nektar Therapeutics (NASDAQ:NKTR) - CSZ News (NASDAQ:NKTR) - October 16 at 6:10 PM
News IconUpdate on Nektar Therapeutics (NASDAQ:NKTR) for the day (NASDAQ:NKTR) - October 15 at 11:06 AM
News IconRating Sentiment Worth Mentioning Today: Is there a Bearish ... - MoneyMakingArticles (NASDAQ:NKTR) - October 14 at 6:11 PM logoShort Interest Declines 13.8% For NKTR (NASDAQ:NKTR) - October 13 at 6:31 PM
News IconResearch Analysts' Recent Ratings Updates for Nektar Therapeutics (NKTR) - Evergreen Investor (NASDAQ:NKTR) - October 13 at 9:59 AM
News IconThe Statistics Don't Lie: Nektar Therapeutics (NASDAQ:NKTR) Earnings Preview - The Voice Registrar (NASDAQ:NKTR) - October 7 at 6:08 PM
News IconLatest Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - October 6 at 11:53 AM
News IconIntraday Active Biotech Stocks News: Nektar Therapeutics (NASDAQ:NKTR), Puma Biotechnology, Inc. (NYSE:PBYI) - The Voice Registrar (NASDAQ:NKTR) - October 5 at 11:36 AM
News IconNew Collaboration Will Evaluate Combination of Opdivo and NKTR-214 (NASDAQ:NKTR) - October 1 at 5:43 PM
News IconNektar Therapeutics (NASDAQ:NKTR) Sale Analysis - Newburgh Press (NASDAQ:NKTR) - October 1 at 11:45 AM logoBrean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy (NASDAQ:NKTR) - September 30 at 11:39 AM logoAnalysts Set EPS Target of $-0.33 For Nektar Therapeutics (NASDAQ:NKTR) - Stocks Daily (NASDAQ:NKTR) - September 29 at 6:21 PM logoBristol-Myers and Nektar Therapeutics to explore potential of Opdivo and NKTR-214 combo (NASDAQ:NKTR) - September 29 at 11:34 AM logoNektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration (NASDAQ:NKTR) - September 29 at 11:34 AM logoNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : September 29, 2016 (NASDAQ:NKTR) - September 29 at 11:34 AM
News IconAnalysts' Recommendations Trending Stocks: Yahoo! Inc. (NASDAQ:YHOO) & Bristol-Myers Squibb Co (NYSE:BMY) - Money News (NASDAQ:NKTR) - September 28 at 6:09 PM
News IconBMS, Nektar to Assess Opdivo/NKTR-214 Combination in Five Tumor Types - Genetic Engineering & Biotechnology News (NASDAQ:NKTR) - September 28 at 6:09 PM
News IconMost Volatile Biotech Stocks- Idera Pharmaceuticals (NASDAQ:IDRA), Nektar Therapeutics (NASDAQ:NKTR) - Seneca Globe (NASDAQ:NKTR) - September 28 at 11:26 AM logoNektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : September 28, 2016 (NASDAQ:NKTR) - September 28 at 11:26 AM logoBristol-Myers Squibb (BMY), Nektar Therapeutics (NKTR) to Evaluate Opdivo + NKTR-214 Combo - (NASDAQ:NKTR) - September 27 at 6:16 PM
News IconBiotech Stocks To Put On Your Watch List: Nektar Therapeutics (NASDAQ:NKTR), Kite Pharma, Inc. (NASDAQ:KITE) - The Voice Registrar (NASDAQ:NKTR) - September 27 at 11:00 AM
News IconScorching Hot Biotech Stocks Tape: ImmunoCellular Therapeutics, Ltd. (IMUC), Nektar Therapeutics (NKTR) - The Independent Republic (NASDAQ:NKTR) - September 27 at 11:00 AM logoNektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration - (NASDAQ:NKTR) - September 27 at 11:00 AM logoNektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb (NASDAQ:NKTR) - September 27 at 11:00 AM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other E (NASDAQ:NKTR) - September 27 at 11:00 AM logoBig Pharma partners with another Bay Area company in cancer immunotherapy quest (NASDAQ:NKTR) - September 27 at 7:43 AM


Nektar Therapeutics (NASDAQ:NKTR) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff